Avid Bioservices Inc (CDMO)

[biopharm]

Bristol-Meyers also declined a request to comment on the issue of financial orphans.

Interesting they had no comment and where is CALICO ?? I still want them as my #1 choice because they have absolutely no pipeline revenues to be concerned about. All these other Big Pharmas will not understand till they lose out an entire stream of Bavi-revenue. Does it seem that some such as BMS are just totally lost in the fact that they will not be bringing in their initial expected revenue "and" they have to pay someone else to even get less than half what they expected ?? Will be interesting how it turns out.... because some (downstream players) will end up with nothing due to Bavi combinations working well with everyone and unless the FDA is lobbied to rule that allows Bavi to be combined with any standard of care, there will be issues. Heck, even if the FDA does allow that.... it will increase SOC approvals due to Bavi/PS Targeting and means less profit for the BP's and more profit for Peregrine.

Unless a buyout occurs and one Big Pharma owns the PS Targeting Platform Technologies... which then brings one full circle FTC monopoly talk lobbied by those others that are without the option to be afforded the right to have a PS Targeting drug with their SOC treatment, that ultimately falls behind the next SOC + Bavi

No wonder why Peregrine has not partnered up yet.... everyone needs them it would seem...

Financial Orphans Looking for Adoption

(b) An existing drug for a new indication with patent protection for the new use. The issue here is whether the new indication for the drug can generate enough revenue to justify expenditure in clinical development. Even if a company had a new-use patent for an existing drug, it might be hard to change the price point from that of its original indication or to enforce a higher price point. Thus even with patent protection, the clinical development of such a drug for a new use may languish. This set of issues is often referred to as repurposing in the literature and even though a few notable examples do exist of successful repurposing by the for-profit sector, this matter remains a lost opportunity.

http://healthaffairs.org/blog/2014/03/06/financial-orphan-therapies-looking-for-adoption/